K E Bethin1, L G Kanapka2, L M Laffel3, S Majidi4, N S Chaytor5, S MacLeish6, R Adams7, N C Foster2. 1. School of Medicine and Biomedical Sciences, University at Buffalo Jacobs, Buffalo, NY. 2. Jaeb Center for Health Research, Tampa, FL. 3. Joslin Diabetes Center, Boston, MA. 4. Barbara Davis Center for Diabetes, Aurora, CO. 5. Elson S. Floyd College of Medicine, Washington State University, Spokane, WA. 6. Rainbow Babies and Children's Hospital, Cleveland, OH, USA. 7. University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Abstract
AIM: Links between autism spectrum disorder (ASD) and autoimmune diseases, including Type 1 diabetes have been proposed. This study assessed the frequency of ASD in children with Type 1 diabetes in the T1D Exchange (T1DX) registry and the impact of ASD on characteristics of children with Type 1 diabetes. METHODS: Analysis included 10 032 participants aged < 18 years (median Type 1 diabetes duration 6.5 years, 48% female, 77% non-Hispanic White). Diagnosis of ASD was defined as autism, Asperger's or pervasive developmental disorder. RESULTS: A diagnosis of ASD was recorded for 159 (1.58%) participants. Those with ASD were predominantly male (88% vs. 51% of those without ASD, P < 0.001) and slightly older (median 14 vs. 13 years, P = 0.022). Occurrence of diabetic ketoacidosis at Type 1 diabetes diagnosis was similar (35% vs. 41%, P = 0.161). Pump use was lower in those with ASD (51% vs. 63%, P = 0.005) but continuous glucose monitor use was similar (24% vs. 27%, P = 0.351). Median HbA1c was slightly lower in those with ASD [68 vs. 69 mmol/mol (8.4% vs. 8.5%), P = 0.006]. This difference was more pronounced after adjusting for confounders. CONCLUSIONS: The frequency of ASD in the T1DX registry was similar to that in the general population. These data show that despite deficits in communication, occurrence of diabetic ketoacidosis was similar in youth with and without ASD. Pump use was less frequent in those with ASD, possibly due to sensory issues, although CGM use did not differ. The lower HbA1c may be due to a more regimented routine with ASD. Because comorbidities such as ASD complicate care of patients with Type 1 diabetes, further research is needed to support these children.
AIM: Links between autism spectrum disorder (ASD) and autoimmune diseases, including Type 1 diabetes have been proposed. This study assessed the frequency of ASD in children with Type 1 diabetes in the T1D Exchange (T1DX) registry and the impact of ASD on characteristics of children with Type 1 diabetes. METHODS: Analysis included 10 032 participants aged < 18 years (median Type 1 diabetes duration 6.5 years, 48% female, 77% non-Hispanic White). Diagnosis of ASD was defined as autism, Asperger's or pervasive developmental disorder. RESULTS: A diagnosis of ASD was recorded for 159 (1.58%) participants. Those with ASD were predominantly male (88% vs. 51% of those without ASD, P < 0.001) and slightly older (median 14 vs. 13 years, P = 0.022). Occurrence of diabetic ketoacidosis at Type 1 diabetes diagnosis was similar (35% vs. 41%, P = 0.161). Pump use was lower in those with ASD (51% vs. 63%, P = 0.005) but continuous glucose monitor use was similar (24% vs. 27%, P = 0.351). Median HbA1c was slightly lower in those with ASD [68 vs. 69 mmol/mol (8.4% vs. 8.5%), P = 0.006]. This difference was more pronounced after adjusting for confounders. CONCLUSIONS: The frequency of ASD in the T1DX registry was similar to that in the general population. These data show that despite deficits in communication, occurrence of diabetic ketoacidosis was similar in youth with and without ASD. Pump use was less frequent in those with ASD, possibly due to sensory issues, although CGM use did not differ. The lower HbA1c may be due to a more regimented routine with ASD. Because comorbidities such as ASD complicate care of patients with Type 1 diabetes, further research is needed to support these children.
Authors: Kellee M Miller; Nicole C Foster; Roy W Beck; Richard M Bergenstal; Stephanie N DuBose; Linda A DiMeglio; David M Maahs; William V Tamborlane Journal: Diabetes Care Date: 2015-06 Impact factor: 19.112
Authors: J-F Lemay; S Lanzinger; D Pacaud; P L Plener; A Fürst-Burger; T Biester; D Hilgard; E Lilienthal; A Galler; G Berger; R W Holl Journal: Pediatr Diabetes Date: 2018-04-14 Impact factor: 4.866
Authors: Dana Dabelea; Elizabeth J Mayer-Davis; Sharon Saydah; Giuseppina Imperatore; Barbara Linder; Jasmin Divers; Ronny Bell; Angela Badaru; Jennifer W Talton; Tessa Crume; Angela D Liese; Anwar T Merchant; Jean M Lawrence; Kristi Reynolds; Lawrence Dolan; Lenna L Liu; Richard F Hamman Journal: JAMA Date: 2014-05-07 Impact factor: 56.272
Authors: Isaac S Kohane; Andrew McMurry; Griffin Weber; Douglas MacFadden; Leonard Rappaport; Louis Kunkel; Jonathan Bickel; Nich Wattanasin; Sarah Spence; Shawn Murphy; Susanne Churchill Journal: PLoS One Date: 2012-04-12 Impact factor: 3.240
Authors: Jamie R Wood; Kellee M Miller; David M Maahs; Roy W Beck; Linda A DiMeglio; Ingrid M Libman; Maryanne Quinn; William V Tamborlane; Stephanie E Woerner Journal: Diabetes Care Date: 2013-01-22 Impact factor: 19.112
Authors: David J Pettitt; Jennifer Talton; Dana Dabelea; Jasmin Divers; Giuseppina Imperatore; Jean M Lawrence; Angela D Liese; Barbara Linder; Elizabeth J Mayer-Davis; Catherine Pihoker; Sharon H Saydah; Debra A Standiford; Richard F Hamman Journal: Diabetes Care Date: 2013-09-16 Impact factor: 19.112
Authors: Samuel Tromans; Guiqing Yao; Regi Alexander; Elizabeta Mukaetova-Ladinska; Reza Kiani; Mohammed Al-Uzri; Verity Chester; Richard Carr; Zoe Morgan; Elpida Vounzoulaki; Traolach Brugha Journal: Clin Pract Epidemiol Ment Health Date: 2020-12-31
Authors: Tamara K Oser; Sean M Oser; Jessica A Parascando; Lee Ann Grisolano; Kanthi Bangalore Krishna; Daniel E Hale; Michelle Litchman; Shideh Majidi; Paul Haidet Journal: J Med Internet Res Date: 2020-06-03 Impact factor: 5.428